4 results
Primary ObjectiveTo evaluate the effect of RVX000222 on the change in burden of coronary atherosclerosis, as measured by percent atheroma volume (PAV), in patients with coronary artery disease and a low level of HDL-C requiring angiography for a…
To measure in vivo biodistribution of 89Zirconium labeled GSK2849330 and characterize its dose receptor occupancy relationship in subjects with advanced HER3 positive solid malignancies.
Primary Objective:To evaluate if treatment with RVX000222 as compared to placebo increases time to thefirst occurrence of narrowly defined MACE. Narrowly defined MACE is defined as a singlecomposite endpoint of CV death or non-fatal MI or stroke.…
To perform a double-blind randomized placebo controlled multicenter study with darbepoetin in infants with MRI confirmed PAIS and to investigate whether darbepoetin can reduce brain injury in neonates who suffered from perinatal arterial ischemic…